TSC Biosample Repository and Natural History Database

Sponsor
National Tuberous Sclerosis Association (Other)
Overall Status
Recruiting
CT.gov ID
NCT05676099
Collaborator
(none)
5,000
23
419
217.4
0.5

Study Details

Study Description

Brief Summary

The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Phlebotomy
  • Procedure: Buccal (cheek) swab
  • Genetic: Genetic Testing
  • Other: Tissue donation after routine clinical procedure

Detailed Description

The purpose of the project which is sponsored by the TSC Alliance is to learn more about tuberous sclerosis complex (TSC) which may lead to new treatments for conditions that affect different areas of the body such as the brain, kidney, heart, lungs, and skin. The TSC Alliance TSC Biosample Repository (BSR) was established to provide a central biobank at the Van Andel Institute (VAI) Biorepository in Grand Rapids, Michigan for the collection of blood, tissues, and cells from a vast number of individuals with TSC.

The TSC Alliance Natural History Database (NHD), established in 2006, will serve as the central repository of de-identified clinical data associated with biosamples collected from individuals with TSC. The NHD research project involves collection of retrospective and prospective private information on individuals with a diagnosis of TSC over their lifespan (i.e., a longitudinal study). The VAI Biorepository will distribute biosamples and NHD data to researchers as approved by the TSC Alliance.

This project also aims to collect biosamples and clinical data on people affected by sporadic lymphangioleiomyomatosis (sporadic LAM). LAM is a common symptom reported in TSC that may occur outside the context of a TSC diagnosis (i.e., sporadic LAM patients).

The collection of biosamples will be at a clinical study site (CSS) such as a TSC Alliance recognized TSC clinic, a non-CSS such as a participant's home, an educational meeting, or by other clinical partners (CP) with institutional review board (IRB) approval of this protocol and informed consent forms. Collection of biosamples may also occur at a non-CSS or by a licensed phlebotomist (e.g., via partnership with mobile phlebotomy companies). The VAI Biorepository will provide collection kits, instructions, and materials to the CSS, non-CSS, CP, or directly to participant.

The CSS, CP, non-CSS, or authorized representative will ship collected biosamples to the VAI Biorepository for processing and storage according to their IRB-approved standard operating procedures. The VAI Biorepository will distribute biosamples to investigators as approved by the TSC Alliance. Their accreditation under the Biorepository Accreditation Program of the College of American Pathologists (CAP) will stand as the governing rules for best practices. Distribution of biosamples will require receipt of the investigator's IRB approval and a material transfer agreement (MTA) executed between the approved investigator and the TSC Alliance.

Clinical data in the NHD associated with a biosample will be provided to an investigator as approved by the Natural History Database-Biosample Repository (NHD-BSR) Steering Committee.

This project is open to individuals of all ages with a diagnosis of tuberous sclerosis complex or lymphangioleiomyomatosis.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
5000 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
TSC Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History Database
Actual Study Start Date :
Jan 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2050
Anticipated Study Completion Date :
Dec 1, 2050

Outcome Measures

Primary Outcome Measures

  1. Natural History data and biosamples including blood, tissue, or other types of biological samples from individuals with TSC [Average 15 years]

    The purposes of this project are to: Collect biosamples such as blood, tissue, fluid, or other types of bodily samples from people with TSC. Collect information about people with TSC over their lifetime.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of tuberous sclerosis complex or lymphangioleiomyomatosis (sporadic LAM).
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alabama Birmingham Birmingham Alabama United States
2 Loma Linda University Children's Hospital Loma Linda California United States
3 University of California Los Angeles Los Angeles California United States 90095
4 Jack & Julia Center for TSC, Oakland Children's Hospital and Research Center Oakland California United States
5 The Children's Hospital Denver Colorado United States
6 Nicklaus Children's Hospital Miami Florida United States
7 Chicago Comer Children's Hospital Neurogenetic Clinic, University of Chicago Chicago Illinois United States
8 University of Iowa Hospitals and Clinics Iowa City Iowa United States
9 TSC Alliance Silver Spring Maryland United States 20910
10 Boston Children's Hospital Boston Massachusetts United States
11 Massachusetts General Hospital Boston Massachusetts United States
12 Minnesota Epilepsy Group Roseville Minnesota United States
13 Washington University in St. Louis Saint Louis Missouri United States 63110
14 New York University Medical Center New York New York United States
15 Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States
16 Cleveland Clinic Foundation Cleveland Ohio United States
17 University of Pennsylvania Medical Center Philadelphia Pennsylvania United States
18 Le Bonheur Children's Hospital Memphis Tennessee United States
19 Texas Scottish Rite Hospital for Children Dallas Texas United States
20 Memorial Hermann-Texas Medical Center (University of Texas Houston) Houston Texas United States
21 Children's National Medical Center Fairfax Virginia United States
22 Centre Hospitalier de L'Université de Montréal (Chum) Montréal Canada
23 Sainte-Justine Université de Montréal Montréal Canada

Sponsors and Collaborators

  • National Tuberous Sclerosis Association

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
National Tuberous Sclerosis Association
ClinicalTrials.gov Identifier:
NCT05676099
Other Study ID Numbers:
  • 15039
First Posted:
Jan 9, 2023
Last Update Posted:
Jan 9, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 9, 2023